KPLPharmaceuticals
Kwality Pharmaceuticals Ltd — Profit & Loss Statement
₹1306.35
-4.50%
Kwality Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -1.71 Cr | -4.05 Cr | 0.00 | — |
| Tax Rate For Calcs | 0.26 | 0.24 | 0.25 | 0.26 | — |
| Normalized EBITDA | 82.31 Cr | 68.14 Cr | 63.03 Cr | 175.17 Cr | — |
| Total Unusual Items | 0.00 | -7.10 Cr | -16.48 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | -7.10 Cr | -16.48 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 39.85 Cr | 23.80 Cr | 19.37 Cr | 119.99 Cr | — |
| Reconciled Depreciation | 18.29 Cr | 19.56 Cr | 14.96 Cr | 10.69 Cr | — |
| Reconciled Cost Of Revenue | 182.49 Cr | 153.18 Cr | 119.42 Cr | 210.19 Cr | — |
| EBITDA | 82.31 Cr | 61.04 Cr | 46.55 Cr | 175.17 Cr | — |
| EBIT | 64.02 Cr | 41.49 Cr | 31.59 Cr | 164.48 Cr | — |
| Net Interest Income | -9.88 Cr | -10.39 Cr | -6.48 Cr | -2.79 Cr | — |
| Interest Expense | 9.88 Cr | 10.39 Cr | 6.02 Cr | 2.92 Cr | — |
| Normalized Income | 39.85 Cr | 29.19 Cr | 31.79 Cr | 119.99 Cr | — |
| Net Income From Continuing And Discontinued Operation | 39.85 Cr | 23.80 Cr | 19.37 Cr | 119.99 Cr | — |
| Total Expenses | 308.10 Cr | 260.42 Cr | 205.26 Cr | 295.21 Cr | — |
| Diluted Average Shares | 1.04 Cr | 1.05 Cr | 1.04 Cr | 1.04 Cr | — |
| Basic Average Shares | 1.04 Cr | 1.05 Cr | 1.04 Cr | 1.04 Cr | — |
| Diluted EPS | 38.36 | 22.76 | 18.67 | 115.64 | — |
| Basic EPS | 38.36 | 22.76 | 18.67 | 115.64 | — |
| Diluted NI Availto Com Stockholders | 39.85 Cr | 23.80 Cr | 19.37 Cr | 119.99 Cr | — |
| Net Income Common Stockholders | 39.85 Cr | 23.80 Cr | 19.37 Cr | 119.99 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 39.85 Cr | 23.80 Cr | 19.37 Cr | 119.99 Cr | — |
| Minority Interests | 0.04 Cr | 0.18 Cr | 0.09 Cr | 0.05 Cr | — |
| Net Income Including Noncontrolling Interests | 39.80 Cr | 23.62 Cr | 19.28 Cr | 119.94 Cr | — |
| Net Income Continuous Operations | 39.80 Cr | 23.62 Cr | 19.28 Cr | 119.94 Cr | — |
| Tax Provision | 14.34 Cr | 7.48 Cr | 6.29 Cr | 41.63 Cr | — |
| Pretax Income | 54.14 Cr | 31.10 Cr | 25.57 Cr | 161.57 Cr | — |
| Other Non Operating Income Expenses | 1.92 Cr | 1.83 Cr | 1.50 Cr | 1.73 Cr | — |
| Special Income Charges | 0.00 | -7.10 Cr | -16.48 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -9.88 Cr | -10.39 Cr | -6.48 Cr | -2.79 Cr | — |
| Interest Expense Non Operating | 9.88 Cr | 10.39 Cr | 6.02 Cr | 2.92 Cr | — |
| Operating Income | 62.10 Cr | 46.75 Cr | 45.77 Cr | 160.97 Cr | — |
| Operating Expense | 125.61 Cr | 107.23 Cr | 85.84 Cr | 85.02 Cr | — |
| Other Operating Expenses | 63.54 Cr | 55.11 Cr | 21.80 Cr | 22.95 Cr | — |
| Depreciation And Amortization In Income Statement | 18.29 Cr | 19.56 Cr | 14.96 Cr | 10.69 Cr | — |
| Depreciation Income Statement | 18.29 Cr | 19.56 Cr | 14.96 Cr | 10.69 Cr | — |
| Gross Profit | 187.71 Cr | 153.99 Cr | 131.61 Cr | 245.99 Cr | — |
| Cost Of Revenue | 182.49 Cr | 153.18 Cr | 119.42 Cr | 210.19 Cr | — |
| Total Revenue | 370.20 Cr | 307.17 Cr | 251.03 Cr | 456.19 Cr | — |
| Operating Revenue | 370.20 Cr | 307.17 Cr | 251.03 Cr | 456.19 Cr | — |
| Interest Income | — | 0.13 Cr | 0.12 Cr | 0.12 Cr | 0.18 Cr |
| Other Special Charges | — | 7.10 Cr | 16.48 Cr | — | 0.02 Cr |
| Interest Income Non Operating | — | 0.13 Cr | 0.12 Cr | 0.12 Cr | 0.18 Cr |
| Selling General And Administration | — | 12.57 Cr | 19.08 Cr | 31.20 Cr | 28.10 Cr |
| Selling And Marketing Expense | — | 7.76 Cr | 12.15 Cr | 27.69 Cr | 25.32 Cr |
| General And Administrative Expense | — | 4.81 Cr | 6.93 Cr | 3.51 Cr | 2.78 Cr |
| Total Other Finance Cost | — | — | 0.59 Cr | — | 77000.00 |
| Rent Expense Supplemental | — | — | — | 0.09 Cr | 0.04 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
| Write Off | — | — | — | 0.16 Cr | 0.00 |
| Rent And Landing Fees | — | — | — | 0.09 Cr | 0.04 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Kwality Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.